Literature DB >> 25103678

Improving hospital performance in the treatment of febrile neutropenia.

Barry Meisenberg1, Jan Clemons, John Ness, Nancy Faust, Mary Clance.   

Abstract

PURPOSE: Febrile neutropenia (FN) remains a common and dangerous complication of cancer treatment. Guidelines from the Infectious Disease Society of America urge initiating antibiotics within 2 h of presentation. We reviewed our institution's performance to identify areas of needed improvement and to design performance improvement steps.
METHODS: FN management was deconstructed into discrete tasks. Experienced practitioners estimated appropriate time allowance for each task. Cycle time analysis data on a baseline cohort (baseline group) identified causes and loci of delay. Based on these data, new processes to bypass roadblocks for timely therapy were introduced. Performance monitoring continued as these changes were implemented (the transitional group) and for 20 months thereafter (the post-intervention group).
RESULTS: Sixty-nine episodes of FN were identified. Ten distinct improvement steps were implemented. Median time to antibiotics was reduced from 252 min, to 188 min and 118 min for the baseline, transitional, and post-intervention groups, respectively (p = 0.0002 for the baseline vs. the post-intervention group comparison). Variability was reduced with the inter-quartile range falling from 174 min (baseline) to 65 min (post-intervention). Despite improvement, there were persisting episodes of delays, due to competing priorities from other patients or decisions to postpone infusion of antibiotics until patients had been admitted. Standardized order sets eliminated improper antibiotic choices as a source of error.
CONCLUSIONS: Improvements in the management of FN can be accomplished and sustained by the focused study of performance of individual tasks, the design of streamlined processes by practitioners, and the ongoing review of performance with feedback to clinical departments.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25103678     DOI: 10.1007/s00520-014-2377-y

Source DB:  PubMed          Journal:  Support Care Cancer        ISSN: 0941-4355            Impact factor:   3.603


  13 in total

1.  Identification of educational and infrastructural barriers to prompt antibiotic delivery in febrile neutropenia: a quality improvement initiative.

Authors:  Erica Burry; Angela Punnett; Ashley Mehta; Jennifer Thull-Freedman; Lisa Robinson; Sumit Gupta
Journal:  Pediatr Blood Cancer       Date:  2011-12-06       Impact factor: 3.167

Review 2.  Improving the immediate management of neutropenic sepsis in the UK: lessons from a national audit.

Authors:  Rachel T Clarke; Janine Warnick; Kate Stretton; Tim J Littlewood
Journal:  Br J Haematol       Date:  2011-04-22       Impact factor: 6.998

3.  Effectiveness and efficiency of root cause analysis in medicine.

Authors:  Albert W Wu; Angela K M Lipshutz; Peter J Pronovost
Journal:  JAMA       Date:  2008-02-13       Impact factor: 56.272

4.  Mortality, morbidity, and cost associated with febrile neutropenia in adult cancer patients.

Authors:  Nicole M Kuderer; David C Dale; Jeffrey Crawford; Leon E Cosler; Gary H Lyman
Journal:  Cancer       Date:  2006-05-15       Impact factor: 6.860

5.  Neutropenic fever: one institution's quality improvement project to decrease time from patient arrival to initiation of antibiotic therapy.

Authors:  Tammy Baltic; Evelyn Schlosser; Marilyn Kay Bedell
Journal:  Clin J Oncol Nurs       Date:  2002 Nov-Dec       Impact factor: 1.027

6.  Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the infectious diseases society of america.

Authors:  Alison G Freifeld; Eric J Bow; Kent A Sepkowitz; Michael J Boeckh; James I Ito; Craig A Mullen; Issam I Raad; Kenneth V Rolston; Jo-Anne H Young; John R Wingard
Journal:  Clin Infect Dis       Date:  2011-02-15       Impact factor: 9.079

7.  The Multinational Association for Supportive Care in Cancer risk index: A multinational scoring system for identifying low-risk febrile neutropenic cancer patients.

Authors:  J Klastersky; M Paesmans; E B Rubenstein; M Boyer; L Elting; R Feld; J Gallagher; J Herrstedt; B Rapoport; K Rolston; J Talcott
Journal:  J Clin Oncol       Date:  2000-08       Impact factor: 44.544

8.  Incidence, cost, and mortality of neutropenia hospitalization associated with chemotherapy.

Authors:  Vincent Caggiano; Richard V Weiss; Timothy S Rickert; Walter T Linde-Zwirble
Journal:  Cancer       Date:  2005-05-01       Impact factor: 6.860

9.  Emergency department waiting times for patients with cancer with febrile neutropenia: a pilot study.

Authors:  Anita Nirenberg; Lisa Mulhearn; Susan Lin; Elaine Larson
Journal:  Oncol Nurs Forum       Date:  2004-07-13       Impact factor: 2.172

10.  Compliance with a critical pathway for the management of febrile neutropenia and impact on clinical outcomes.

Authors:  J Zuckermann; L B Moreira; P Stoll; L M Moreira; R S Kuchenbecker; C A Polanczyk
Journal:  Ann Hematol       Date:  2007-10-16       Impact factor: 3.673

View more
  3 in total

1.  A nurse-led protocol improves the time to first dose intravenous antibiotics in septic patients post chemotherapy.

Authors:  Graeme Mattison; Matthew Bilney; Phil Haji-Michael; Tim Cooksley
Journal:  Support Care Cancer       Date:  2016-07-25       Impact factor: 3.603

2.  A systematic approach for studying the signs and symptoms of fever in adult patients: the fever assessment tool (FAST).

Authors:  Nancy J Ames; John H Powers; Alexandra Ranucci; Kyungsook Gartrell; Li Yang; Mark VanRaden; Nancy Kline Leidy; Gwenyth R Wallen
Journal:  Health Qual Life Outcomes       Date:  2017-04-27       Impact factor: 3.186

Review 3.  Chemotherapy-Induced Neutropenia and Febrile Neutropenia in the US: A Beast of Burden That Needs to Be Tamed?

Authors:  Ralph Boccia; John Glaspy; Jeffrey Crawford; Matti Aapro
Journal:  Oncologist       Date:  2022-08-05       Impact factor: 5.837

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.